Welcome to our dedicated page for Iqvia Hldgs SEC filings (Ticker: IQV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IQVIA Holdings Inc. (NYSE: IQV) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other documents filed with the U.S. Securities and Exchange Commission. IQVIA’s filings confirm that its common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades on the New York Stock Exchange under the symbol IQV.
IQVIA uses Form 8-K to report material events such as quarterly financial results, amendments to its credit agreements and leadership or board changes. For example, the company has filed 8-K reports describing financial results for specific quarters, an amendment to its Fifth Amended and Restated Credit Agreement and the planned transition of its chief financial officer. Other 8-K filings cover the appointment of new directors and related governance matters.
For investors analyzing IQVIA, these filings help explain the company’s financial condition, capital structure and key corporate developments. They also provide context for IQVIA’s role as a global provider of clinical research services, commercial insights and healthcare intelligence, including how it finances its operations and manages governance and leadership transitions.
On Stock Titan, SEC filings for IQVIA are updated as new documents are posted to the SEC’s EDGAR system. AI-powered summaries help interpret lengthy filings by highlighting important sections, such as descriptions of material agreements, financial updates or changes in executive roles. Users can review 8-Ks for event-driven information and refer to other filing types, such as annual and quarterly reports when available, to gain a more complete view of IQVIA’s business and risks.
IQV (issuer) — Notice of proposed sale under Form 144. A shareholder filed to sell up to 56,557 shares of common stock, with an aggregate market value of $12,460,983.24. The approximate sale date listed is 10/29/2025, and the shares are listed on the NYSE. Morgan Stanley Smith Barney LLC is named as the broker.
The securities were acquired via Stock Appreciation Rights on 10/29/2025, with 56,557 shares indicated and cash noted as the nature of payment. The filing lists 170,300,000 shares outstanding, providing context for the potential sale size.
IQVIA Holdings (IQV) filed a Form 144 notice indicating an intended sale of 4,000 shares of common stock through Morgan Stanley Smith Barney LLC. The filing lists an aggregate market value of $878,819.60 for the planned sale, with an approximate sale date of 10/29/2025 on the NYSE.
The shares were acquired on 10/29/2025 via Stock Appreciation Rights from the issuer, with a stated amount acquired of 4,000 and cash as the nature of payment. The filing also notes 170,300,000 shares outstanding for context. Form 144 is a notice of proposed sale by an affiliate or other reporting person and does not, by itself, guarantee that a sale will occur.
IQVIA Holdings Inc. reported third‑quarter results with steady growth and active balance sheet management. Q3 2025 revenue was $4.1 billion versus $3.896 billion a year ago, and diluted EPS was $1.93 compared with $1.55. Segment revenue reached $1.631 billion in Technology & Analytics Solutions, $2.260 billion in Research & Development Solutions, and $209 million in Contract Sales & Medical Solutions. Q3 income from operations was $553 million. For the first nine months, revenue totaled $11.946 billion and diluted EPS was $4.86.
Operating cash flow for the nine months was $1.919 billion, supporting $1.032 billion of share repurchases (6.4 million shares). The company issued $2.0 billion of 6.250% senior notes due 2032 and amended its credit facilities, including a $1.985 billion Term B-5 loan to refinance prior tranches. Total debt principal was $15.034 billion and cash was $1.814 billion at quarter‑end. Remaining performance obligations were $34.4 billion, with about 30% expected to convert within 12 months. Goodwill increased to $15.948 billion, reflecting acquisitions. Common shares outstanding were 170.3 million as of October 20, 2025. Legal disputes with Veeva were fully resolved in August 2025 with no payment by either party.
IQVIA Holdings Inc. furnished an 8-K announcing it issued a press release with financial results for the third quarter ended September 30, 2025. The full text of the release was posted on the company’s website and is included as Exhibit 99.1. Pursuant to General Instruction B.2, the Item 2.02 information is furnished, not filed, and is not subject to Section 18 of the Exchange Act or incorporated into other filings unless specifically referenced.
IQVIA Holdings Inc. appointed Michael J. Fedock as its next Executive Vice President and Chief Financial Officer, effective February 28, 2026, as part of a planned CFO succession. He will succeed Ronald E. Bruehlman, who will retire from the CFO role on that date and become Senior Advisor to the CEO to support a smooth transition.
Mr. Fedock has more than 25 years of healthcare industry experience and has held several senior finance roles at IQVIA since 2016, including Senior Vice President, Financial Planning and Analysis, and CFO roles for key business units. In connection with his promotion, his annual base salary will increase to $750,000, and he will have an annual cash incentive target equal to 100% of base salary, along with eligibility for long-term incentives under IQVIA’s 2017 Incentive and Stock Award Plan and standard executive benefit plans.
Harris Associates L.P. and Harris Associates, Inc. filed an Amendment No. 1 to Schedule 13G reporting beneficial ownership of IQVIA Holdings Inc. common stock. The filing shows an aggregate of 11,753,182 shares, representing 6.8% of the class, with sole voting power over 10,291,782 shares and sole dispositive power over 11,753,182 shares. The Schedule identifies IQVIA's principal executive office at 2400 Ellis Road, Durham, NC.
The statement notes the shares are held in the ordinary course of business and were not acquired to change or influence control of the issuer. The filing is dated as an event on 06/30/2025 and signed on 08/14/2025 by Joseph J. Allessie as General Counsel and Secretary.
FAQ
What is the current stock price of Iqvia Hldgs (IQV)?
What is the market cap of Iqvia Hldgs (IQV)?
